Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.

Dutta, Aditya

Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. [electronic resource] - European urology 10 2017 - 499-506 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

1873-7560

10.1016/j.eururo.2017.03.031 doi


5-alpha Reductase Inhibitors--adverse effects
Aged
Animals
Biomarkers, Tumor--genetics
Chemotherapy, Adjuvant
Clinical Decision-Making
DNA Mutational Analysis
Dutasteride--adverse effects
Finasteride--adverse effects
Homeodomain Proteins--genetics
Humans
Male
Mice, Knockout
Middle Aged
Mutation
Neoadjuvant Therapy
Neoplasm Staging
Patient Selection
Precision Medicine
Predictive Value of Tests
Prostatectomy
Prostatic Intraepithelial Neoplasia--drug therapy
Prostatic Neoplasms--drug therapy
Retrospective Studies
Time Factors
Transcription Factors--genetics
Treatment Outcome